Jiangsu Hengrui Medicine Co., Ltd
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor
- First Posted Date
- 2019-07-09
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT04013048
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on Fluzoparib
- First Posted Date
- 2019-07-08
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04011124
- Locations
- 🇨🇳
First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer
- First Posted Date
- 2019-06-27
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 280
- Registration Number
- NCT04000295
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China
A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT03995472
- Locations
- 🇦🇺
John Flynn Private Hospital, Tugun, Queensland, Australia
🇦🇺Sydney Southwest Private Hospital, Liverpool, New South Wales, Australia
🇦🇺Scientia Clinical Research, Randwick, New South Wales, Australia
A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 1192
- Registration Number
- NCT03980054
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Malignancy.
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 129
- Registration Number
- NCT03976882
- Locations
- 🇨🇳
Najing Bayi Hospital, Nanjing, Jiangsu, China
Metabolism and Disposition of [14C] Herombopag in Chinese Healthy Human Subjects
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03977805
- Locations
- 🇨🇳
The first affiliated hospital of Suzhou university, Suzhou, Jiangsu, China
A Study to Evaluate the Safety and Efficacy of DDO-3055 in Healthy Volunteers and Patients With Chronic Kidney Disease
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT03976115
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension
- Conditions
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT03971929
- Locations
- 🇨🇳
The second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Hangzhou, China
A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-05-29
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 426
- Registration Number
- NCT03966898
- Locations
- 🇨🇳
Nayima Bayaxi, Shanghai, China